While the cardiovascular benefits of sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM) are well-established, their role in cancer patients with T2DM - a population at heightened risk of cardiovascular complications due to both malignancy and cardiotoxic therapies - remains unclear. The gene discussed is SLC5A2; the disease is cancer.